ATGGF (Actinogen Medical) Total Equity : $15.18 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Actinogen Medical Total Equity?

Actinogen Medical's total equity for the quarter that ended in Dec. 2024 was $15.18 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Actinogen Medical Total Equity Historical Data

The historical data trend for Actinogen Medical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical Total Equity Chart

Actinogen Medical Annual Data

Trend

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Equity

Get a 7-Day Free Trial

7.52

13.35

15.28

9.00

13.08

Actinogen Medical Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Equity	Get a 7-Day Free Trial															10.85	9.00	8.02	13.08	15.18

Actinogen Medical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Actinogen Medical's Total Equity for the fiscal year that ended in Jun. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2024 )	-	Total Liabilities(Q: Jun. 2024 )
	=	14.151	-	1.072
	=	13.08

Actinogen Medical's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	16.104	-	0.925
	=	15.18

Actinogen Medical Total Equity Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (OTCPK:ATGGF) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

3AC:Germany ACW:Australia

Address

109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website

https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.